Get started
Author

George Chrysos

Observed names: G Chrysos, G. Chrysos
ORCID: 0000-0002-8272-8446
Observed ORCID: 0000-0002-8272-8446
OpenAlex ID: A5062046607
Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae : experience from a national registry study
2020 · I Karaiskos, G L Daikos, et al. · Journal of Antimicrobial Chemotherapy · 101
Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms
1992 · J.D. Williams, J.P. Maskell, et al. · Journal of Antimicrobial Chemotherapy · 74
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial
2024 · Evangelos J Giamarellos-Bourboulis, Athanasios Siampanos, et al. · The Lancet Respiratory Medicine · 67
Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece
2020 · Giota Touloumi, Natasa Kalpourtzi, et al. · PLoS ONE · 44
PDF
Prevalence of drug resistance among HIV-1 treatment-naive patients in Greece during 2003–2015: Transmitted drug resistance is due to onward transmissions
2017 · D. Paraskevis, E. Kostaki, et al. · Infection Genetics and Evolution · 33
Body composition changes in protease inhibitor‐naive HIV‐infected patients treated with two nucleoside reverse transcriptase inhibitors
2002 · G Tsekes, G Chrysos, et al. · HIV Medicine · 33
Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial
2021 · Konstantinos Tsiakos, Antonios Tsakiris, et al. · Infectious Diseases and Therapy · 24
PDF
Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia
2022 · Charilaos Samaras, Evdoxia Kyriazopoulou, et al. · Cytokine · 18
Coxsackievirus infection associated with acute pancreatitis.
2004 · George Chrysos, Stelios Kokkoris, et al. · PubMed · 17
Developing a Tool for Differentiation Between Bacterial and Viral Respiratory Infections Using Myxovirus Resistance Protein A and C-Reactive Protein
2023 · Konstantina Iliopoulou, Panagiotis Koufargyris, et al. · Infectious Diseases and Therapy · 16
PDF
Virological and Immunological Response to HAART Therapy in a Community-Based Cohort of HIV-1-Positive Individuals
2001 · Giota Touloumi, Vasilis Paparizos, et al. · HIV Clinical Trials · 15
Neurolisteriosis mimicking herpes simplex encephalitis in an immunocompromized patient
2006 · John Protopsaltis, Stelios Kokkoris, et al. · Scandinavian Journal of Infectious Diseases · 11
Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.
2007 · George Chrysos, Sotirios Mikros, et al. · PubMed · 10
Intracranial haemorrhage possibly related to Tipranavir in an HIV-1 patient with cryptococcal meningitis
2008 · G. Chrysos, S. Gerakari, et al. · Journal of Infection · 9
Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia
2026 · Ritu Banerjee, Lauren Komarow, et al. · JAMA · 7
Anakinra efficacy in COVID-19 pneumonia guided by soluble urokinase plasminogen activator receptor: Association with the inflammatory burden of the host
2024 · Evdoxia Kyriazopoulou, Karolina Akinosoglou, et al. · International Journal of Antimicrobial Agents · 7
Clarithromycin for improved clinical outcomes in community-acquired pneumonia: A subgroup analysis of the ACCESS trial
2024 · Karolina Akinosoglou, Konstantinos Leventogiannis, et al. · International Journal of Antimicrobial Agents · 7
The HIV patient profile in 2013 and 2003: Results from the Greek AMACS cohort
2018 · Nikos Pantazis, Maria Chini, et al. · PLoS ONE · 7
PDF
Heparin-binding Protein Levels Predict Unfavorable Outcome in Covid-19 Pneumonia: a Post Hoc Analysis of the Save Trial
2024 · Evdoxia Kyriazopoulou, George N. Dalekos, et al. · Shock · 4
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions
2017 · Ellen C. Caniglia, Andrew Phillips, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 3
Pharmacokinetic interactions of ceftazidime and frusemide.
1995 · G Chrysos, P Gargalianos, et al. · PubMed · 3
Molecular pathways driving clarithromycin benefit in community-acquired pneumonia: analysis of the ACCESS randomised trial
2026 · Emmanouil Stylianakis, Nikolaos Kakavoulis, et al. · EBioMedicine · 2
PDF
A randomized controlled trial of precision bezlotoxumab treatment for Clostridioides difficile infection
2026 · Christos Psarrakis, Nikolaos-Renatos Tziolos, et al. · Cell Reports Medicine · 2
PDF
Treatment Modifications and Treatment-Limiting Toxicities or Side Effects: Risk Factors and Temporal Trends
2015 · Nikos Pantazis, Mina Psichogiou, et al. · AIDS Research and Human Retroviruses · 2
Incidence and risk factors of chronic renal disease in a cohort of Greek HIV‐1‐infected adults
2012 · V Sakka, G Bakoyannis, et al. · Journal of the International AIDS Society · 1
Works count: 30
Citation count: 518
H-index: 11
I10-index: 13
Year
Topic
Type